search
Back to results

Ketorolac-an Option for Post Operative Pain Management After Elective Cardiac Surgery. (KOPAC)

Primary Purpose

Coronary Artery Disease, Post Operative Pain, Analgesia

Status
Completed
Phase
Phase 4
Locations
Pakistan
Study Type
Interventional
Intervention
Ketorolac Injection
Paracetamol
Sponsored by
National Institute of Cardiovascular Diseases, Pakistan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Coronary Artery Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Males and females between 18 years and above of age.
  • Undergoing elective cardiac surgery.
  • American Society of Anesthesiology (ASA) Physical Class 3 or 4.

Exclusion Criteria:

  • • Patients pre-planned for delayed extubation (due to moderate to severe pulmonary artery hypertension, poor right ventricular function, rhythm disturbances or unstable vitals)

    • Low cardiac output (cardiac index < 2.0 l/min/m2, using transesophageal echocardiography, intraoperatively) after weaning off cardiopulmonary bypass or paitients already having pre-op ejection fraction < 30%.
    • Patients not comfortably ventilated or oxygenated, requiring high doses of sedation and neuromuscular blockage.
    • Sensitivity or allergy to nonsteroidal anti-inflammatory drugs.
    • History of peptic ulcer or gastrointestinal bleeding.
    • Serum creatinine = 2.0 mg/dl or increase in serum creatinine of = 0.5 mg/dl or 25% within the preceding 10 days.
    • Hepatic dysfunction.
    • Bleeding disorder.

Sites / Locations

  • National Institute of Cardiovascular Diseases

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Ketorolac

Paracetamol

Arm Description

Ketorolac 30mg 8 hourly for 48 hours post-operatively

Paracetamol 1gm 6 hourly for 48 hours post-operatively

Outcomes

Primary Outcome Measures

Reduction in pain severity
Post operative analgesic assessment using Visual Analogue Scale VAS: a 10 cm long line between the two endpoints (0 to 10). 0: no pain at all 10: worst pain ever felt The mark that the patient pointed to, defined the patient's pain. For the purposes of this study "adequate pain relief" was defined as achieving a pain score of four or less, this designation was also included on the VAS scale and explained to the patients so that they may indicate numbers higher than four if they felt any pain.

Secondary Outcome Measures

Reduction in Opioid usage (if any)
Reduction in Nalbuphine administration as an opioid analgesic
Time to Extubation in hours
Time taken from patient's entry into the surgical ICU after elective cardiac surgery, till the time Endotracheal tube was removed.
Total amount of blood (in milliliters) collected, in the under-water sealed drain bottles, via chest drainage tubes
The total amount (in milliliters) of blood collected via chest drains into the under-water sealed drain bottles

Full Information

First Posted
April 30, 2022
Last Updated
September 28, 2022
Sponsor
National Institute of Cardiovascular Diseases, Pakistan
search

1. Study Identification

Unique Protocol Identification Number
NCT05361824
Brief Title
Ketorolac-an Option for Post Operative Pain Management After Elective Cardiac Surgery.
Acronym
KOPAC
Official Title
Ketorolac Verses Paracetamol as an Adjunct to Nalbuphine in Post Operative Pain Management in Elective Cardiac Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Completed
Study Start Date
January 1, 2021 (Actual)
Primary Completion Date
June 30, 2021 (Actual)
Study Completion Date
July 6, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Institute of Cardiovascular Diseases, Pakistan

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
OBJECTIVE: The purpose of this study was to compare the efficacy of Ketorolac versus Paracetamol as an adjunct to Nalbuphine in the management of post-operative pain following elective cardiac surgery. STUDY DESIGN: Randomized (single-blind) control trial. SAMPLING TECHNIQUE: Computer generated, randomized selection of patients with 50% probability of assignment into either group. PLACE AND STUDY DURATION: (single center) SICU at the National Institute of Cardiovascular Diseases Hospital, Karachi over a period of six months, from January 1, 2021 up to June 30, 2021. METHODS: Sixty patients (30 in each group) were randomly assigned to receive either Paracetamol (control) or Ketorolac (treatment), along with the usual Nalbuphine infusion, over the first 48 hours postoperatively. The control group received injection Paracetamol 1gm six hourly, whereas treatment group received injection Ketorolac 30mg eight hourly. PRIMARY OUTCOME: The VAS (pain score) was evaluated at 6, 12, 18 and 24 hours post-extubation and a score of 4 or less was taken as a cut-off for adequate pain control. SECONDARY OUTCOMES: The time taken to extubation postoperatively. The total dose of Nalbuphine administered to each patient and total chest tube drainage recorded over 48 hours postoperatively.
Detailed Description
DATA COLLECTION: Computer randomization was done for the numbers 1 to 60, having 50% probability of being in either of two groups: Ketorolac (treatment) or Paracetamol (control). After randomizing each number into either group, which ever patient (consenting and meeting the inclusion criteria) came, was allotted these numbers consecutively, as they presented for elective cardiac surgery. Thus randomly allocating the presenting patients into either Ketorolac/treatment (30 patients) and Paracetamol/control (30 patients). Each patient was explained about the VAS pain rating score twice; first at preoperative interview and second time after they recovered their alert state in the SICU post operatively( at time of extubation). The patients were taught to finger-point their intensity of pain on a line between two endpoints: marked 0 to 10. Mark at '0' meant no pain at all and '10' worst pain ever felt. The number that the patient pointed to, defined the patient's pain. For the purposes of this study "adequate pain relief" was defined as achieving a pain score of four or less, this designation was also included on the VAS scale and explained to the patients so that they may indicate numbers higher than four if they felt any pain. Standard anaesthesia was given in the operative room, total analgesia given intra-operatively was 0.4 mg/kg Nalbuphine (not exceeding 30mg). After completion of the surgery all patients were shifted to SICU. Initially both groups received a bolus dose of 10mg Nalbuphine and then an infusion of Nalbuphine was started at 2.5mg/hr as maintenance, up to 24 hours post-operatively. In addition, (according to randomization) the patients in treatment group received Ketorolac 30mg 8 hourly for 48 hours post-operatively and the patients control group received Paracetamol 1gm 6 hourly for 48 hours post-operatively. Postoperative analgesia assessment using VAS was performed at 6 hours, 12 hours, 18 hours and 24 hours postextubation. Time taken to extubation, total dose of Nalbuphine administered to each patient and total chest tube drainage were also recorded over 24 hours postoperatively.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease, Post Operative Pain, Analgesia, Coronary Artery Bypass Grafting Surgery

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Computer generated, randomized selection of patients with 50% probability of assignment into either group Treatment group : Ketorolac group Control Group: Paracetamol
Masking
Participant
Masking Description
100ml infusion bottles identical in every aspect, except a unique label on them which was only known to investigator.
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ketorolac
Arm Type
Experimental
Arm Description
Ketorolac 30mg 8 hourly for 48 hours post-operatively
Arm Title
Paracetamol
Arm Type
Active Comparator
Arm Description
Paracetamol 1gm 6 hourly for 48 hours post-operatively
Intervention Type
Drug
Intervention Name(s)
Ketorolac Injection
Other Intervention Name(s)
Toradol
Intervention Description
dosage form: intravenous dosage: 30mg frequency: 8 hours apart (TDS) duration: for 48 hours post operatively
Intervention Type
Drug
Intervention Name(s)
Paracetamol
Other Intervention Name(s)
Bofalgan, Provas
Intervention Description
dosage form: intravenous dosage: 1gm frequency: 6 hours apart (QID) duration: for 48 hours post operatively
Primary Outcome Measure Information:
Title
Reduction in pain severity
Description
Post operative analgesic assessment using Visual Analogue Scale VAS: a 10 cm long line between the two endpoints (0 to 10). 0: no pain at all 10: worst pain ever felt The mark that the patient pointed to, defined the patient's pain. For the purposes of this study "adequate pain relief" was defined as achieving a pain score of four or less, this designation was also included on the VAS scale and explained to the patients so that they may indicate numbers higher than four if they felt any pain.
Time Frame
6 hours apart for total 24 hours(6 hours, 12 hours , 18 hours and 24 hours) post extubation.
Secondary Outcome Measure Information:
Title
Reduction in Opioid usage (if any)
Description
Reduction in Nalbuphine administration as an opioid analgesic
Time Frame
Within 48 hours postoperatively
Title
Time to Extubation in hours
Description
Time taken from patient's entry into the surgical ICU after elective cardiac surgery, till the time Endotracheal tube was removed.
Time Frame
Within 24 hours postoperatively
Title
Total amount of blood (in milliliters) collected, in the under-water sealed drain bottles, via chest drainage tubes
Description
The total amount (in milliliters) of blood collected via chest drains into the under-water sealed drain bottles
Time Frame
Within 48 hours postoperatively

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males and females between 18 years and above of age. Undergoing elective cardiac surgery. American Society of Anesthesiology (ASA) Physical Class 3 or 4. Exclusion Criteria: • Patients pre-planned for delayed extubation (due to moderate to severe pulmonary artery hypertension, poor right ventricular function, rhythm disturbances or unstable vitals) Low cardiac output (cardiac index < 2.0 l/min/m2, using transesophageal echocardiography, intraoperatively) after weaning off cardiopulmonary bypass or paitients already having pre-op ejection fraction < 30%. Patients not comfortably ventilated or oxygenated, requiring high doses of sedation and neuromuscular blockage. Sensitivity or allergy to nonsteroidal anti-inflammatory drugs. History of peptic ulcer or gastrointestinal bleeding. Serum creatinine = 2.0 mg/dl or increase in serum creatinine of = 0.5 mg/dl or 25% within the preceding 10 days. Hepatic dysfunction. Bleeding disorder.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dr Maaida Muzaffar, FCPS
Organizational Affiliation
National Institute of Cardiovascular Diseases, Pakistan
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Institute of Cardiovascular Diseases
City
Karachi
State/Province
Sindh
Country
Pakistan

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Only patient's unique hospital ID will be provided if required

Learn more about this trial

Ketorolac-an Option for Post Operative Pain Management After Elective Cardiac Surgery.

We'll reach out to this number within 24 hrs